CARLSBAD, Calif., Aug. 17, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.
(NASDAQ: IONS), the leader in antisense therapeutics, today announced that
management will present a company overview at the following investor
conferences:
* Southern California Investor Conference on Thursday, August 24, 2017 in
Newport Beach, CA;
* 2017 Wells Fargo Healthcare Conference on Wednesday, September 6, 2017
in Boston, MA; and
* 15th Annual Morgan Stanley Global Healthcare Conference on Wednesday,
September 13, 2017 in New York, NY.
The above listed dates are subject to change. Details on presentation times
or changes to presentation dates can be found on the Company's website. Please
check www.ionispharma.com for the latest information.
A live webcast of the presentations will be available on the "Investors &
Media" section of the Ionis website. The replays will be available within 48
hours and will be archived for a limited time.
ABOUT IONIS PHARMACEUTICALS, INC.Ionis is the leading company in
RNA-targeted drug discovery and development focused on developing drugs for
patients who have the highest unmet medical needs, such as those patients with
severe and rare diseases. Using its proprietary antisense technology, Ionis has
created a large pipeline of first-in-class or best-in-class drugs, with over
three dozen drugs in development. SPINRAZA(r) (nusinersen) has been approved in
the U.S., Europe, Japan and Canada for the treatment of spinal muscular atrophy
(SMA). Biogen is responsible for commercializing SPINRAZA. Drugs that have
successfully completed Phase 3 studies include inotersen (IONIS-TTRRx), an
antisense drug Ionis is developing to treat patients with TTR amyloidosis, and
volanesorsen, an antisense drug discovered by Ionis and co-developed by Ionis
and Akcea Therapeutics to treat patients with either familial chylomicronemia
syndrome or familial partial lipodystrophy. Akcea, an affiliate of Ionis, is a
biopharmaceutical company focused on developing and commercializing drugs to
treat patients with serious cardiometabolic diseases caused by lipid disorders.
If approved, volanesorsen will be commercialized through Ionis' affiliate,
Akcea. Both inotersen and volanesorsen are progressing toward regulatory
filings for marketing authorization. Ionis' patents provide strong and
extensive protection for its drugs and technology. Additional information about
Ionis is available at www.ionispharma.com .
IONIS' FORWARD-LOOKING STATEMENTThis press release includes forward-looking
statements regarding Ionis Pharmaceuticals' business and the therapeutic and
commercial potential of Ionis' technologies and products in development,
including SPINRAZA, inotersen and volanesorsen. Any statement describing Ionis'
goals, expectations, financial or other projections, intentions or beliefs is a
forward-looking statement and should be considered an at-risk statement. Such
statements are subject to certain risks and uncertainties, particularly those
inherent in the process of discovering, developing and commercializing drugs
that are safe and effective for use as human therapeutics, and in the endeavor
of building a business around such drugs. Ionis' forward-looking statements
also involve assumptions that, if they never materialize or prove correct,
could cause its results to differ materially from those expressed or implied by
such forward-looking statements. Although Ionis' forward-looking statements
reflect the good faith judgment of its management, these statements are based
only on facts and factors currently known by Ionis. As a result, you are
cautioned not to rely on these forward-looking statements. These and other
risks concerning Ionis' programs are described in additional detail in Ionis'
annual report on Form 10-K for the year ended December 31, 2016, and its most
recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of
these and other documents are available from the Company.
In this press release, unless the context requires otherwise, "Ionis,"
"Company," "we," "our," and "us" refers to Ionis Pharmaceuticals and its
subsidiaries.
Ionis Pharmaceuticals(tm) is a trademark of Ionis Pharmaceuticals, Inc.
Akcea Therapeutics(tm) is a trademark of Ionis Pharmaceuticals, Inc.
SPINRAZA(r) is a registered trademark of Biogen.
View original content with
multimedia:http://www.prnewswire.com/news-releases/ionis-pharmaceuticals-to-pres
ent-at-upcoming-investor-conferences-300505642.html
SOURCE Ionis Pharmaceuticals, Inc.
(TS:IONS;)